<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265524</url>
  </required_header>
  <id_info>
    <org_study_id>CTST-21</org_study_id>
    <nct_id>NCT01265524</nct_id>
  </id_info>
  <brief_title>Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multi-center Study Comparing CLP Versus Placebo in Heart Failure Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorbent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaterra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sorbent Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of CLP on serum potassium and signs and
      symptoms of fluid overload in heart failure patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Potassium</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in serum potassium from baseline to Week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Loss at Week 1</measure>
    <time_frame>Baseline and 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Loss at Week 2</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Improving by at Least One NYHA Functional Class From Baseline to Week 8</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWT Distance at Week 8</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Increase in the 6 minute walk test (6MWT) distance from baseline to Week 8. The test was performed according to the American Thoracic Society (ATS)Guidelines 2002.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CLP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigational drug: 15 g CLP per day given as capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLP</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>CLP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure with New York Heart Association (NYHA) Classification III or IV

          -  Hospitalization for heart failure decompensation associated with fluid overload within
             the last six months

          -  Chronic kidney disease

          -  Must be able to understand study procedures and willing and able to provide written
             informed consent

        Exclusion Criteria:

          -  No hospitalization within 4 weeks of Baseline Visit

          -  In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine,
             gastrointestinal, neurological or other disease or condition that makes the patients
             study participation unsafe

          -  History or presence of gastrointestinal conditions such as severe constipation or
             gastrointestinal tract strictures

          -  Current dialysis patient, or anticipated need for dialysis during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Detlef Albrecht, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sorbent Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Costanzo MR, Heywood JT, Massie BM, Iwashita J, Henderson L, Mamatsashvili M, Sisakian H, Hayrapetyan H, Sager P, van Veldhuisen DJ, Albrecht D. A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease. Eur J Heart Fail. 2012 Aug;14(8):922-30. doi: 10.1093/eurjhf/hfs074. Epub 2012 May 21.</citation>
    <PMID>22613585</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <results_first_submitted>January 3, 2013</results_first_submitted>
  <results_first_submitted_qc>March 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2013</results_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although 113 subjects were randomized, 2 subjects did not receive study drug and were removed from the analysis as pre- specified in the SAP.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Investigational Drug: CLP</title>
          <description>Investigational drug: 15 g CLP per day given as capsules</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Investigational Drug: CLP</title>
          <description>Investigational drug: 15g CLP per day given as capsules</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="8"/>
                    <measurement group_id="B2" value="70" spread="10"/>
                    <measurement group_id="B3" value="69" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" spread="13.6"/>
                    <measurement group_id="B2" value="75.1" spread="16.2"/>
                    <measurement group_id="B3" value="75.2" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <units>ml/min/1.73m3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="14.2"/>
                    <measurement group_id="B2" value="44.9" spread="17.3"/>
                    <measurement group_id="B3" value="45" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Functional Class</title>
          <description>NYHA Functional Classes are I, II, III, and IV A brief summary of the classes is included below. Class I: patients with cardiac disease but without resulting limitations of physical activity Class II: patients with cardiac disease with slight limitations to physical activity Class III: patients with cardiac disease with marked limitations of physical activity Class IV: patients with cardiac disease resulting in an inability to carry out physical activity without discomfort</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Potassium</title>
        <description>Change in serum potassium from baseline to Week 8.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Drug: CLP</title>
            <description>Investigational drug: 15g CLP per day given as capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Potassium</title>
          <description>Change in serum potassium from baseline to Week 8.</description>
          <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.348"/>
                    <measurement group_id="O2" value="0.05" spread="0.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Loss at Week 1</title>
        <time_frame>Baseline and 1 week</time_frame>
        <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Drug: CLP</title>
            <description>Investigational drug: 15g CLP per day given as capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Loss at Week 1</title>
          <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="1.5"/>
                    <measurement group_id="O2" value="0.11" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</non_inferiority_desc>
            <p_value>0.014</p_value>
            <p_value_desc>Corrections for multiplicity were not performed and P values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Continuous or ordinal data were analyzed using RM-ANCOVA using change from baseline values to compare CLP and placebo treatments.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Loss at Week 2</title>
        <time_frame>Baseline and 2 weeks</time_frame>
        <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Drug: CLP</title>
            <description>Investigational drug: 15g CLP per day given as capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Loss at Week 2</title>
          <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="1.8"/>
                    <measurement group_id="O2" value="0.29" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 4</title>
        <description>The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 4.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational Drug: CLP</title>
            <description>Investigational drug: 15g CLP per day given as capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 4</title>
          <description>The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 4.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 8</title>
        <description>The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 8.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational Drug: CLP</title>
            <description>Investigational drug: 15g CLP per day given as capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 8</title>
          <description>The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 8.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Improving by at Least One NYHA Functional Class From Baseline to Week 8</title>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Drug: CLP</title>
            <description>Investigational drug: 15g CLP per day given as capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Improving by at Least One NYHA Functional Class From Baseline to Week 8</title>
          <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <p_value_desc>Corrections for multiplicity were not performed and P values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Continuous or ordinal data were analyzed using RM-ANCOVA using change from baseline values to compare CLP and placebo treatments.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6MWT Distance at Week 8</title>
        <description>Increase in the 6 minute walk test (6MWT) distance from baseline to Week 8. The test was performed according to the American Thoracic Society (ATS)Guidelines 2002.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Drug: CLP</title>
            <description>Investigational drug: 15g CLP per day given as capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: capsules</description>
          </group>
        </group_list>
        <measure>
          <title>6MWT Distance at Week 8</title>
          <description>Increase in the 6 minute walk test (6MWT) distance from baseline to Week 8. The test was performed according to the American Thoracic Society (ATS)Guidelines 2002.</description>
          <population>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</population>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="53.39"/>
                    <measurement group_id="O2" value="19.7" spread="39.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.</non_inferiority_desc>
            <p_value>0.072</p_value>
            <p_value_desc>Corrections for multiplicity were not performed and P values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Continuous or ordinal data were analyzed using RM-ANCOVA using change from baseline values to compare CLP and placebo treatments.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Investigational Drug: CLP</title>
          <description>Investigational drug: 15g CLP per day given as capsules</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A standard confidentiality agreement is in place.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Dittrich, MD FACC</name_or_title>
      <organization>Sorbent Therapeutics</organization>
      <phone>858-405-1429</phone>
      <email>hdittrich@sorbent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

